Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783897 | PMC |
| http://dx.doi.org/10.1007/s11523-021-00863-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Early Clinical Outcomes of Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma: A Real-World Comparison with First-Line or Later-Line Treatment.
Drugs Real World Outcomes
December 2024
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, 2-1-1 Idaidori, Yahaba-cho, Shiwa-gun, Iwate, 028-3694, Japan.
Article Synopsis
- Durvalumab plus tremelimumab (Durva/Treme) is a newly approved treatment for unresectable hepatocellular carcinoma (u-HCC) in Japan, and researchers assessed its real-world outcomes.
- A study evaluated 22 patients at Iwate Medical University who received Durva/Treme, comparing outcomes between those treated as first-line vs. later-line therapy.
- Results showed no significant differences in progression-free survival, objective response rate, disease control rate, or adverse event incidence between the two groups, suggesting Durva/Treme is effective and safe for u-HCC patients regardless of treatment line.
Peripheral blood immune parameters, response, and adverse events after neoadjuvant chemotherapy plus durvalumab in early-stage triple-negative breast cancer.
Breast Cancer Res Treat
November 2024
Department of Internal Medicine, Section of Medical Oncology, Yale University, New Haven, CT, USA.
Purpose: We evaluated T- and B-cell receptor (TCR and BCR) repertoire diversity and 38 serum cytokines in pre- and post-treatment peripheral blood of 66 patients with triple-negative breast cancer (TNBC) who received neoadjuvant chemotherapy plus durvalumab and assessed associations with pathologic response and immune-related adverse events (irAEs) during treatment.
Methods: Genomic DNA was isolated from buffy coat for TCR and BCR clonotype profiling using the Immunoseq platform and diversity was quantified with Pielou's evenness index. MILLIPLEX MAP Human Cytokine/Chemokine Magnetic Bead Panel was used to measure serum cytokine levels, which were compared between groups using moderated t-statistic with Benjamini-Hochberg correction for multiple testing.
Author Correction: Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group.
Nat Commun
June 2024
GINECO (Groupe d'Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire, Paris, France.
Publisher Correction: A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC.
Nat Cancer
January 2024
Radiation Oncology, University of Colorado Denver at Anschutz Medical Campus, Aurora, CO, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!